Full name
17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis
NCT Number
NCT05583344
Geography
US
Non-US
Locations
Argentina, Australia, Belgium, Canada, France, Greece, India, Italy, Japan, Republic of Korea, Mexico, Panama, Puerto Rico, Spain, Turkey, United Kingdom, United States
Primary Endpoints
- Percentage of Participants Achieving ≥ 1 Stage Improvement in Histological Fibrosis with no Worsening of NASH - F3 Cohort. At Week 52
- Percentage of Participants Achieving NASH Resolution with no Worsening of Fibrosis - F3 Cohort. At Week 52
External Link
https://clinicaltrials.gov/study/NCT05583344
Order
1
Disease
Version
Phase
2b
Status
Active, not recruiting